UA72532C2 - Monoclonal antibody and combination of monoclonal antibodies for detecting prion protein as an indication of transmissible spongiform encephalopathies - Google Patents
Monoclonal antibody and combination of monoclonal antibodies for detecting prion protein as an indication of transmissible spongiform encephalopathies Download PDFInfo
- Publication number
- UA72532C2 UA72532C2 UA2002021252A UA2002021252A UA72532C2 UA 72532 C2 UA72532 C2 UA 72532C2 UA 2002021252 A UA2002021252 A UA 2002021252A UA 2002021252 A UA2002021252 A UA 2002021252A UA 72532 C2 UA72532 C2 UA 72532C2
- Authority
- UA
- Ukraine
- Prior art keywords
- monoclonal antibody
- tissue
- pgr
- specified
- epitope
- Prior art date
Links
- 108091000054 Prion Proteins 0.000 title claims abstract description 34
- 102000029797 Prion Human genes 0.000 title claims abstract description 33
- 208000024777 Prion disease Diseases 0.000 title abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 37
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 36
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 31
- 241000282849 Ruminantia Species 0.000 claims abstract description 18
- 238000003018 immunoassay Methods 0.000 claims abstract description 11
- 241000282326 Felis catus Species 0.000 claims abstract description 6
- 241000282414 Homo sapiens Species 0.000 claims abstract description 5
- 210000001519 tissue Anatomy 0.000 claims description 61
- 241001494479 Pecora Species 0.000 claims description 57
- 239000000203 mixture Substances 0.000 claims description 33
- 238000001514 detection method Methods 0.000 claims description 28
- 241000282994 Cervidae Species 0.000 claims description 25
- 241001465754 Metazoa Species 0.000 claims description 22
- 239000003153 chemical reaction reagent Substances 0.000 claims description 22
- 210000004556 brain Anatomy 0.000 claims description 21
- 210000003563 lymphoid tissue Anatomy 0.000 claims description 21
- 241000283690 Bos taurus Species 0.000 claims description 20
- 101150096336 PGR gene Proteins 0.000 claims description 14
- 238000001574 biopsy Methods 0.000 claims description 13
- 241000283707 Capra Species 0.000 claims description 12
- 210000000826 nictitating membrane Anatomy 0.000 claims description 10
- 210000001165 lymph node Anatomy 0.000 claims description 8
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 8
- 238000011888 autopsy Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 108010067770 Endopeptidase K Proteins 0.000 claims description 6
- 210000004408 hybridoma Anatomy 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 4
- 235000019253 formic acid Nutrition 0.000 claims description 4
- 108090000631 Trypsin Proteins 0.000 claims description 3
- 102000004142 Trypsin Human genes 0.000 claims description 3
- 230000001413 cellular effect Effects 0.000 claims description 3
- 239000012588 trypsin Substances 0.000 claims description 3
- 241000282339 Mustela Species 0.000 claims description 2
- 230000029087 digestion Effects 0.000 claims description 2
- 210000000952 spleen Anatomy 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims 2
- 238000010306 acid treatment Methods 0.000 claims 1
- 239000003593 chromogenic compound Substances 0.000 claims 1
- 230000008014 freezing Effects 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 241000894007 species Species 0.000 abstract description 23
- 208000015181 infectious disease Diseases 0.000 abstract description 15
- 230000009257 reactivity Effects 0.000 abstract description 13
- 241000282412 Homo Species 0.000 abstract description 12
- 230000035945 sensitivity Effects 0.000 abstract description 4
- 241000772415 Neovison vison Species 0.000 abstract description 3
- 244000144972 livestock Species 0.000 abstract description 3
- 208000010544 human prion disease Diseases 0.000 abstract 2
- 101710182788 Protein-glutamine gamma-glutamyltransferase E Proteins 0.000 description 44
- 208000008864 scrapie Diseases 0.000 description 28
- 108090000765 processed proteins & peptides Proteins 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- 241000282979 Alces alces Species 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 239000000047 product Substances 0.000 description 12
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 11
- 208000005881 bovine spongiform encephalopathy Diseases 0.000 description 11
- 238000003745 diagnosis Methods 0.000 description 10
- 238000003119 immunoblot Methods 0.000 description 10
- 239000000872 buffer Substances 0.000 description 9
- 238000002991 immunohistochemical analysis Methods 0.000 description 9
- 239000012528 membrane Substances 0.000 description 9
- 210000005013 brain tissue Anatomy 0.000 description 8
- 238000012744 immunostaining Methods 0.000 description 8
- 210000002569 neuron Anatomy 0.000 description 8
- 108700028369 Alleles Proteins 0.000 description 7
- 108020004705 Codon Proteins 0.000 description 7
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000002405 diagnostic procedure Methods 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 230000001886 ciliary effect Effects 0.000 description 5
- 230000002055 immunohistochemical effect Effects 0.000 description 5
- 238000003364 immunohistochemistry Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000008506 pathogenesis Effects 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 101150002981 Rgr gene Proteins 0.000 description 4
- 244000309464 bull Species 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 210000002741 palatine tonsil Anatomy 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 210000003934 vacuole Anatomy 0.000 description 4
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 3
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 3
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- 206010018341 Gliosis Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 235000015278 beef Nutrition 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 208000017580 chronic wasting disease Diseases 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- 244000144992 flock Species 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 210000001259 mesencephalon Anatomy 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 210000004498 neuroglial cell Anatomy 0.000 description 3
- 210000004179 neuropil Anatomy 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 2
- 208000032274 Encephalopathy Diseases 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 235000019687 Lamb Nutrition 0.000 description 2
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical class O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 108700026244 Open Reading Frames Proteins 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 108010032838 Sialoglycoproteins Proteins 0.000 description 2
- 102000007365 Sialoglycoproteins Human genes 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229960002685 biotin Drugs 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 239000011616 biotin Substances 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000007910 cell fusion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000007387 gliosis Effects 0.000 description 2
- 210000004884 grey matter Anatomy 0.000 description 2
- 244000038280 herbivores Species 0.000 description 2
- 238000010562 histological examination Methods 0.000 description 2
- 238000007489 histopathology method Methods 0.000 description 2
- 230000000642 iatrogenic effect Effects 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 230000004770 neurodegeneration Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 229940016590 sarkosyl Drugs 0.000 description 2
- 108700004121 sarkosyl Proteins 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- KSAVQLQVUXSOCR-UHFFFAOYSA-M sodium lauroyl sarcosinate Chemical compound [Na+].CCCCCCCCCCCC(=O)N(C)CC([O-])=O KSAVQLQVUXSOCR-UHFFFAOYSA-M 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000009210 therapy by ultrasound Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 208000037956 transmissible mink encephalopathy Diseases 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 102100027824 3'(2'),5'-bisphosphate nucleotidase 1 Human genes 0.000 description 1
- 101150065898 AVT5 gene Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 241000304496 Asian elephant endotheliolytic herpesvirus Species 0.000 description 1
- 108050001427 Avidin/streptavidin Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 101100532690 Caenorhabditis elegans mau-2 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 244000108321 Diplazium esculentum Species 0.000 description 1
- 235000014276 Diplazium esculentum Nutrition 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101000666172 Homo sapiens Protein-glutamine gamma-glutamyltransferase E Proteins 0.000 description 1
- 101100033916 Homo sapiens RGR gene Proteins 0.000 description 1
- 102100036309 MAU2 chromatid cohesion factor homolog Human genes 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 238000011887 Necropsy Methods 0.000 description 1
- 101100366988 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) stu-1 gene Proteins 0.000 description 1
- 101100491259 Oryza sativa subsp. japonica AP2-2 gene Proteins 0.000 description 1
- 101100084198 Ovis aries PGR gene Proteins 0.000 description 1
- 101000983121 Ovis aries Pancreatic prohormone Proteins 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000035977 Rare disease Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 235000011449 Rosa Nutrition 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000016063 arterial thoracic outlet syndrome Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000037875 astrocytosis Diseases 0.000 description 1
- 230000007341 astrogliosis Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004081 cilia Anatomy 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006059 cover glass Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000005546 dideoxynucleotide Substances 0.000 description 1
- 238000001085 differential centrifugation Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000537 electroencephalography Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 201000006061 fatal familial insomnia Diseases 0.000 description 1
- 208000037957 feline spongiform encephalopathy Diseases 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 108060003552 hemocyanin Proteins 0.000 description 1
- 238000012333 histopathological diagnosis Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 206010051040 hyper-IgE syndrome Diseases 0.000 description 1
- 230000002895 hyperchromatic effect Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 238000013115 immunohistochemical detection Methods 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000019143 inherited prion disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 206010023497 kuru Diseases 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 210000005004 lymphoid follicle Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000001767 medulla oblongata Anatomy 0.000 description 1
- 210000000274 microglia Anatomy 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000037432 silent mutation Effects 0.000 description 1
- 238000003307 slaughter Methods 0.000 description 1
- 230000003393 splenic effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2872—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against prion molecules, e.g. CD230
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2828—Prion diseases
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Zoology (AREA)
- General Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Microbiology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biotechnology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/353,348 US6261790B1 (en) | 1999-07-15 | 1999-07-15 | Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies |
| PCT/US2000/019211 WO2001005426A1 (en) | 1999-07-15 | 2000-07-14 | Monoclonal antibodies and antibody cocktail for detection of prion protein as an indication of transmissible spongiform encephalopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA72532C2 true UA72532C2 (en) | 2005-03-15 |
Family
ID=23388730
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UA2002021252A UA72532C2 (en) | 1999-07-15 | 2000-07-14 | Monoclonal antibody and combination of monoclonal antibodies for detecting prion protein as an indication of transmissible spongiform encephalopathies |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6261790B1 (cs) |
| EP (1) | EP1212082A4 (cs) |
| JP (1) | JP2003504087A (cs) |
| KR (1) | KR20020034158A (cs) |
| CN (1) | CN1450909A (cs) |
| AU (1) | AU773078B2 (cs) |
| BG (1) | BG106415A (cs) |
| BR (1) | BR0012468A (cs) |
| CA (1) | CA2379349A1 (cs) |
| CZ (1) | CZ295412B6 (cs) |
| EA (1) | EA005239B1 (cs) |
| EE (1) | EE200200009A (cs) |
| GE (1) | GEP20043256B (cs) |
| HU (1) | HUP0202183A2 (cs) |
| IL (1) | IL147517A0 (cs) |
| MX (1) | MXPA02000445A (cs) |
| NO (1) | NO20020190L (cs) |
| NZ (1) | NZ517075A (cs) |
| OA (1) | OA11991A (cs) |
| PL (1) | PL199345B1 (cs) |
| SK (1) | SK282002A3 (cs) |
| TR (1) | TR200200071T2 (cs) |
| UA (1) | UA72532C2 (cs) |
| WO (1) | WO2001005426A1 (cs) |
| ZA (1) | ZA200200969B (cs) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3495738B2 (ja) | 1995-09-14 | 2004-02-09 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 天然ＰｒＰｓｃ特異的抗体 |
| US7041807B1 (en) | 1999-06-23 | 2006-05-09 | Caprion Pharmaceuticals, Inc. | Antibodies to a YYX epitope of a mammalian prion protein |
| US7098317B1 (en) * | 2000-05-23 | 2006-08-29 | Blood Transfusion Center Of Slovenia | Antibodies capable to selectively detect prion PrPSc isoforms |
| US6537548B1 (en) * | 2000-07-27 | 2003-03-25 | The Regents Of The University Of California | Antibodies specific for ungulate PrP |
| WO2002046236A1 (fr) * | 2000-12-08 | 2002-06-13 | Fujirebio Inc. | Anticorps monoclonal dirigé contre un prion anormal, procédé de production correspondant, et procédé d'essai immunologique l'utilisant |
| DE10120562C2 (de) * | 2001-04-26 | 2003-04-10 | Horst Messer | Verfahren zur Diagnose von übertragbaren spongiformen Enzephalopathien |
| KR20020033126A (ko) * | 2002-03-08 | 2002-05-04 | 김용선 | 병원성 프리온 단백의 n말단의 비효소적 당화반응 최종산물의 검출에 의한 프리온 질환의 진단 |
| US20040175775A1 (en) * | 2002-11-08 | 2004-09-09 | Neil Cashman | Method of detecting PrPsc in eye fluid |
| JP4485367B2 (ja) | 2002-12-03 | 2010-06-23 | パソゲン リムーバル アンド ダイアグノスティック テクノロジーズ インコーポレイテッド | プリオンタンパク質リガンドおよび使用方法 |
| US20050282238A1 (en) * | 2003-09-23 | 2005-12-22 | Bowen David J | High-sensitivity chemiluminescent ELISA prion detection method |
| AU2005209592B2 (en) | 2004-09-30 | 2012-07-12 | Ortho-Clinical Diagnostics, Inc. | Peptides for discrimination of prions |
| GB0501564D0 (en) * | 2005-01-25 | 2005-03-02 | Univ Cambridge Tech | Test for prion disease |
| WO2006102099A2 (en) * | 2005-03-18 | 2006-09-28 | The Regents Of The University Of California | ANTIBODIES SPECIFIC FOR HUMAN AND BOVINE PrP |
| JP4724816B2 (ja) * | 2005-09-06 | 2011-07-13 | シャープ株式会社 | タンパク質の測定方法 |
| AU2006287299B2 (en) | 2005-09-09 | 2012-08-23 | Novartis Ag | Prion-specific peptoid reagents |
| US20070196863A1 (en) * | 2006-02-17 | 2007-08-23 | Hanson Technologies, Inc. | Prion protein detection |
| EP2142934B1 (en) * | 2007-04-04 | 2011-10-26 | Novartis AG | Prion assay |
| US20100233176A1 (en) | 2008-10-06 | 2010-09-16 | Cashman Neil R | Methods and systems for predicting misfolded protein epitopes |
| WO2011028961A2 (en) | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Anti-botulism antibody coformulations |
| US20110059079A1 (en) * | 2009-09-04 | 2011-03-10 | Xoma Technology Ltd. | Antibody Coformulations |
| CN102558349B (zh) * | 2012-01-12 | 2013-12-11 | 吉林大学 | 一种识别天然结构梅花鹿朊蛋白的单克隆抗体及制备方法 |
| CN104031148B (zh) * | 2014-05-15 | 2018-03-13 | 中国科学院动物研究所 | 针对人PrPc的单克隆抗体及其应用 |
| JP2023504699A (ja) * | 2019-12-04 | 2023-02-06 | エイシー イミューン ソシエテ アノニム | 治療および診断のための新規な分子 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4806627A (en) | 1987-05-29 | 1989-02-21 | Research Foundation Of Mental Hygiene Inc. | Hybrid cell lines producing monoclonal antibodies dircted against scrapie-associated fibril proteins |
| AU675053B2 (en) | 1991-12-03 | 1997-01-23 | Proteus Molecular Design Limited | Fragments of prion proteins |
| US5565186A (en) | 1994-05-13 | 1996-10-15 | The Regents Of The University Of California | Method of detecting prions in a sample and transgenic animal used for same |
| JP3495738B2 (ja) | 1995-09-14 | 2004-02-09 | ザ レジェンツ オブ ザ ユニバーシティー オブ カリフォルニア | 天然ＰｒＰｓｃ特異的抗体 |
| DE19741607A1 (de) * | 1997-09-20 | 1999-03-25 | Prionics Ag | Synthetische Polypeptide zur Diagnose und Therapie von Prionerkrankungen |
| US6165784A (en) | 1997-10-14 | 2000-12-26 | The United States Of America As Represented By The Secretary Of Agriculture | Antibodies for the detection of prion protein as an indication of transmissible spongiform encephalopathies |
-
1999
- 1999-07-15 US US09/353,348 patent/US6261790B1/en not_active Expired - Lifetime
-
2000
- 2000-07-14 JP JP2001510480A patent/JP2003504087A/ja active Pending
- 2000-07-14 WO PCT/US2000/019211 patent/WO2001005426A1/en active IP Right Grant
- 2000-07-14 TR TR2002/00071T patent/TR200200071T2/xx unknown
- 2000-07-14 GE GEAP20006329A patent/GEP20043256B/en unknown
- 2000-07-14 CA CA002379349A patent/CA2379349A1/en not_active Abandoned
- 2000-07-14 NZ NZ517075A patent/NZ517075A/en unknown
- 2000-07-14 EP EP00950351A patent/EP1212082A4/en not_active Withdrawn
- 2000-07-14 AU AU63466/00A patent/AU773078B2/en not_active Ceased
- 2000-07-14 KR KR1020027000598A patent/KR20020034158A/ko not_active Application Discontinuation
- 2000-07-14 SK SK28-2002A patent/SK282002A3/sk unknown
- 2000-07-14 BR BR0012468-0A patent/BR0012468A/pt not_active IP Right Cessation
- 2000-07-14 EA EA200200164A patent/EA005239B1/ru not_active IP Right Cessation
- 2000-07-14 MX MXPA02000445A patent/MXPA02000445A/es not_active Application Discontinuation
- 2000-07-14 CN CN00812776A patent/CN1450909A/zh active Pending
- 2000-07-14 UA UA2002021252A patent/UA72532C2/uk unknown
- 2000-07-14 OA OA1200200014A patent/OA11991A/en unknown
- 2000-07-14 HU HU0202183A patent/HUP0202183A2/hu unknown
- 2000-07-14 EE EEP200200009A patent/EE200200009A/xx unknown
- 2000-07-14 IL IL14751700A patent/IL147517A0/xx unknown
- 2000-07-14 PL PL354512A patent/PL199345B1/pl not_active IP Right Cessation
- 2000-07-14 CZ CZ200225A patent/CZ295412B6/cs not_active IP Right Cessation
-
2002
- 2002-01-14 NO NO20020190A patent/NO20020190L/no unknown
- 2002-02-04 ZA ZA200200969A patent/ZA200200969B/en unknown
- 2002-02-14 BG BG106415A patent/BG106415A/bg unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK282002A3 (en) | 2002-09-10 |
| EP1212082A4 (en) | 2005-09-21 |
| EP1212082A1 (en) | 2002-06-12 |
| CZ200225A3 (cs) | 2002-08-14 |
| BG106415A (bg) | 2002-12-29 |
| NZ517075A (en) | 2004-03-26 |
| PL354512A1 (en) | 2004-01-26 |
| BR0012468A (pt) | 2002-10-22 |
| MXPA02000445A (es) | 2002-07-02 |
| KR20020034158A (ko) | 2002-05-08 |
| EA005239B1 (ru) | 2004-12-30 |
| WO2001005426A1 (en) | 2001-01-25 |
| GEP20043256B (en) | 2004-06-25 |
| OA11991A (en) | 2006-04-18 |
| AU773078B2 (en) | 2004-05-13 |
| US6261790B1 (en) | 2001-07-17 |
| AU6346600A (en) | 2001-02-05 |
| EA200200164A1 (ru) | 2002-10-31 |
| HUP0202183A2 (en) | 2002-10-28 |
| CA2379349A1 (en) | 2001-01-25 |
| TR200200071T2 (tr) | 2005-05-23 |
| NO20020190D0 (no) | 2002-01-14 |
| CN1450909A (zh) | 2003-10-22 |
| JP2003504087A (ja) | 2003-02-04 |
| EE200200009A (et) | 2003-02-17 |
| CZ295412B6 (cs) | 2005-08-17 |
| PL199345B1 (pl) | 2008-09-30 |
| ZA200200969B (en) | 2003-04-30 |
| NO20020190L (no) | 2002-03-12 |
| IL147517A0 (en) | 2002-08-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA72532C2 (en) | Monoclonal antibody and combination of monoclonal antibodies for detecting prion protein as an indication of transmissible spongiform encephalopathies | |
| AU756955B2 (en) | Methods for detection of prion protein as an indication of transmissible spongiform encephalopathies | |
| O’Rourke et al. | Monoclonal antibody F89/160.1. 5 defines a conserved epitope on the ruminant prion protein | |
| US7674599B2 (en) | Methods of using antibodies to detect alpha-synuclein in fluid samples | |
| JP2010054514A (ja) | 短いエピトープに対して向けられる複数組のディジタル抗体、およびその使用 | |
| KR20190066027A (ko) | 진단 분석에 사용하기 위한 단백질 항원으로서 rep 단백질 | |
| CA2250800C (en) | Method for the detection of prion diseases | |
| CN105548561A (zh) | 阿尔茨海默病的诊断药和诊断方法 | |
| US9068993B2 (en) | Diagnostic assays and methods of use for detection of filarial infection | |
| CA2671633A1 (en) | Diagnostic agent for mesothelioma, diagnosis kit for mesothelioma, and diagnosis method for mesothelioma | |
| EP0929813B1 (en) | Diagnosis of spongiform disease | |
| WO2004009640A1 (ja) | 抗菌性ペプチドに対する抗体及びその利用 | |
| Parish et al. | Shinagawa,“Detection of PrP" in Sheep at the Preclinical Stage of Scrapie and its Significance for Diagnosis of | |
| CA2634638A1 (en) | A bioassay and peptides for use therein | |
| JP2005029501A (ja) | モノクローナル抗体、ハイブリドーマ、腸管毒素の検査方法及びその除去方法 |